Literature DB >> 27235615

Pharmacologic Therapy in Men's Health: Hypogonadism, Erectile Dysfunction, and Benign Prostatic Hyperplasia.

Kathryn E Berkseth1, Arthi Thirumalai2, John K Amory3.   

Abstract

This article reviews current pharmacologic treatment options for 3 common men's health concerns: hypogonadism, erectile dysfunction (ED), and benign prostatic hyperplasia (BPH). Specific topics addressed include: management of male hypogonadism using testosterone replacement therapy, use of oral phosphodiesterase inhibitors as first-line therapy for men with ED and the utility of intraurethral and intrapenile alprostadil injections for patients who do not respond to oral medications, and the role of alpha1-adrenergic antagonists, 5-alpha-reductase inhibitors, anticholinergic agents, and herbal therapies in the management of BPH.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Benign prostatic hyperplasia (BPH); Erectile dysfunction (ED); Male hypogonadism; Pharmacologic treatment

Mesh：

Substances：

Year:  2016        PMID： 27235615      PMCID： PMC5639879          DOI： 10.1016/j.mcna.2016.03.006

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN： 0025-7125            Impact factor:   5.456


  38 in total

1.  Effect of dutasteride on the risk of prostate cancer.

Authors:  Gerald L Andriole; David G Bostwick; Otis W Brawley; Leonard G Gomella; Michael Marberger; Francesco Montorsi; Curtis A Pettaway; Teuvo L Tammela; Claudio Teloken; Donald J Tindall; Matthew C Somerville; Timothy H Wilson; Ivy L Fowler; Roger S Rittmaster
Journal:  N Engl J Med       Date:  2010-04-01       Impact factor: 91.245

2.  Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence.

Authors:  S B Levine; S E Althof; L A Turner; C B Risen; D R Bodner; E D Kursh; M I Resnick
Journal:  J Urol       Date:  1989-01       Impact factor: 7.450

3.  A multi-institutional observational study of testosterone levels after testosterone pellet (Testopel(®)) insertion.

Authors:  Andrew R McCullough; Mohit Khera; Irwin Goldstein; Wayne J G Hellstrom; Abraham Morgentaler; Laurence A Levine
Journal:  J Sex Med       Date:  2012-01-12       Impact factor: 3.802

4.  Comparative pharmacokinetics of testosterone enanthate and testosterone cyclohexanecarboxylate as assessed by serum and salivary testosterone levels in normal men.

Authors:  T Schürmeyer; E Nieschlag
Journal:  Int J Androl       Date:  1984-06

5.  A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.

Authors:  B Djavan; M Marberger
Journal:  Eur Urol       Date:  1999       Impact factor: 20.096

6.  Efficacy and safety of once-daily tadalafil in men with erectile dysfunction who reported no successful intercourse attempts at baseline.

Authors:  Ridwan Shabsigh; Allen D Seftel; Edward D Kim; Xiao Ni; Patrick R Burns
Journal:  J Sex Med       Date:  2012-10-04       Impact factor: 3.802

Review 7.  Erectile dysfunction.

Authors:  Rany Shamloul; Hussein Ghanem
Journal:  Lancet       Date:  2012-10-05       Impact factor: 79.321

8.  The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.

Authors:  Mohammad Reza Safarinejad
Journal:  BJU Int       Date:  2010-01-08       Impact factor: 5.588

9.  Liver damage from long-term methyltestosterone.

Authors:  D Westaby; S J Ogle; F J Paradinas; J B Randell; I M Murray-Lyon
Journal:  Lancet       Date:  1977-08-06       Impact factor: 79.321

10.  Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia.

Authors:  Hunter Wessells; Johnny Roy; John Bannow; John Grayhack; Alvin M Matsumoto; Lisa Tenover; Richard Herlihy; William Fitch; Richard Labasky; Stephen Auerbach; Raul Parra; Jacob Rajfer; Jennifer Culbertson; Michael Lee; Mark A Bach; Joanne Waldstreicher
Journal:  Urology       Date:  2003-03       Impact factor: 2.649
View more
  1 in total

Review 1.  Adult-onset hypogonadism: evaluation and role of testosterone replacement therapy.

Authors:  Andrew J Davidiuk; Gregory A Broderick
Journal:  Transl Androl Urol       Date:  2016-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.